The Risk of Latent Tuberculosis Reactivation in COVID-19 Therapy

The Risk of Latent Tuberculosis Reactivation in COVID-19 Therapy

Authors

  • Ghina Mutiara Abas Master’s Programme in Biomedical Sciences Faculty of Medicine, Universitas Indonesia, Jl. Salemba Raya No.4, Jakarta, Indonesia
  • Fithriyah Sjatha Departement of Microbiology, Faculty of Medicine, Universitas Indonesia, Jl. Pegangsaan Timur No.16, Jakarta, Indonesia
  • Yeva Rosana Departement of Microbiology, Faculty of Medicine, Universitas Indonesia, Jl. Pegangsaan Timur No.16, Jakarta, Indonesia

DOI:

https://doi.org/10.18051/JBiomedKes.2023.v6.363-372

Keywords:

COVID-19, LTBI, reactivation TB, immunosuppressant, corticosteroid

Abstract

The high mortality rate among COVID-19 patients in the acute respiratory distress syndrome (ARDS) phase led to the administration of immunosuppressive drugs. Corticosteroids could block inflammation caused by cytokine storm, and prevent pneumonia, edema, fibrosis, and ARDS. Even though it was believed to have beneficial effects, corticosteroids can suppress T CD4+ and CD8+ cell-mediated immunity reaction through decreased IFNγ production thus leading to reactivation of latent Tuberculosis (LTBI). Therefore, the usage of corticosteroids in the ARDS phase of COVID-19 patients should be carefully given; pre-screening of LTBI may be done to avoid Tuberculosis reactivation.

Downloads

Download data is not yet available.

Downloads

Published

2023-12-31

How to Cite

1.
Abas GM, Sjatha F, Rosana Y. The Risk of Latent Tuberculosis Reactivation in COVID-19 Therapy. J Biomedika dan Kesehat [Internet]. 2023 Dec. 31 [cited 2024 Mar. 5];6(3):363-72. Available from: https://jbiomedkes.org/index.php/jbk/article/view/306

Issue

Section

Review Article
Loading...